DERM Stock Overview
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
Journey Medical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.13|
|52 Week High||US$10.20|
|52 Week Low||US$2.48|
|1 Month Change||-27.21%|
|3 Month Change||-31.36%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-67.05%|
Recent News & Updates
US$12.00: That's What Analysts Think Journey Medical Corporation (NASDAQ:DERM) Is Worth After Its Latest Results
Journey Medical Corporation ( NASDAQ:DERM ) investors will be delighted, with the company turning in some strong...
|DERM||US Pharmaceuticals||US Market|
Return vs Industry: Insufficient data to determine how DERM performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how DERM performed against the US Market.
|DERM Average Weekly Movement||14.6%|
|Pharmaceuticals Industry Average Movement||11.5%|
|Market Average Movement||8.0%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: DERM is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: DERM's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution.
Journey Medical Fundamentals Summary
|DERM fundamental statistics|
Is DERM overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DERM income statement (TTM)|
|Cost of Revenue||US$29.88m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.62|
|Net Profit Margin||-60.28%|
How did DERM perform over the long term?See historical performance and comparison
Is DERM undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for DERM?
Other financial metrics that can be useful for relative valuation.
|What is DERM's n/a Ratio?|
Price to Sales Ratio vs Peers
How does DERM's PS Ratio compare to its peers?
|DERM PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
Price-To-Sales vs Peers: DERM is good value based on its Price-To-Sales Ratio (0.7x) compared to the peer average (83.9x).
Price to Earnings Ratio vs Industry
How does DERM's PE Ratio compare vs other companies in the U.S. Pharmaceuticals Industry?
Price-To-Sales vs Industry: DERM is good value based on its Price-To-Sales Ratio (0.7x) compared to the US Pharmaceuticals industry average (4x)
Price to Sales Ratio vs Fair Ratio
What is DERM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||0.7x|
|Fair PS Ratio||3.6x|
Price-To-Sales vs Fair Ratio: DERM is good value based on its Price-To-Sales Ratio (0.7x) compared to the estimated Fair Price-To-Sales Ratio (3.6x).
Share Price vs Fair Value
What is the Fair Price of DERM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: DERM ($3.13) is trading below our estimate of fair value ($51.12)
Significantly Below Fair Value: DERM is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DERM's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Journey Medical forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DERM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: DERM is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: DERM is expected to become profitable in the next 3 years.
Revenue vs Market: DERM's revenue (13.6% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: DERM's revenue (13.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DERM's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Journey Medical performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: DERM is currently unprofitable.
Growing Profit Margin: DERM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if DERM's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare DERM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DERM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.7%).
Return on Equity
High ROE: DERM has a negative Return on Equity (-110.14%), as it is currently unprofitable.
Discover strong past performing companies
How is Journey Medical's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: DERM's short term assets ($90.3M) exceed its short term liabilities ($61.0M).
Long Term Liabilities: DERM's short term assets ($90.3M) exceed its long term liabilities ($18.5M).
Debt to Equity History and Analysis
Debt Level: DERM has more cash than its total debt.
Reducing Debt: Insufficient data to determine if DERM's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DERM has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if DERM has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is Journey Medical current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DERM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DERM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DERM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DERM's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as DERM has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Claude Maraoui (54 yo)
Mr. Claude Maraoui is Founder and Director of Journey Medical Corporation since 2016 and its President and Chief Executive Officer since September 2014. Mr. Maraoui has experience in launching and commerci...
CEO Compensation Analysis
Compensation vs Market: Claude's total compensation ($USD1.57M) is above average for companies of similar size in the US market ($USD758.64K).
Compensation vs Earnings: Claude's compensation has been consistent with company performance over the past year.
Experienced Board: DERM's board of directors are not considered experienced ( 0.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: DERM only recently listed within the past 12 months.
Journey Medical Corporation's employee growth, exchange listings and data sources
- Name: Journey Medical Corporation
- Ticker: DERM
- Exchange: NasdaqCM
- Founded: 2014
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$54.561m
- Shares outstanding: 17.43m
- Website: https://journeymedicalcorp.com
Number of Employees
- Journey Medical Corporation
- 9237 East Via de Ventura Boulevard
- Suite 105
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/24 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.